Please see profiles on each of the Directors below:
Andrew Joy (Chairman)
Andrew Joy joined the Board in March 2012. He was one of the founding Partners of Cinven where he continues as a Senior Advisor. He is a Senior Advisor of Stonehage Fleming Family & Partners Group and Chairman of the private equity investment committee. Mr Joy has been Chairman & Director of numerous growing Companies over the past 30 years. He is former Chairman of the BVCA (British Venture Capital and Private Equity Associate) and Director of the EVCA.
Sven Borho joined the Board in March 2006 and is a founding Partner of OrbiMed, the Company’s Investment Manager. He heads the public equity team and is the portfolio manager for OrbiMed’s public equity and hedge funds. Sven has played an integral role in the growth of OrbiMed’s asset management activities. He started his career in 1991 when he joined OrbiMed’s predecessor firm as a Senior Analyst covering European pharmaceutical firms and biotechnology companies worldwide. In 1993, Sven was promoted to portfolio manager. He studied business administration at Bayreuth University in Germany and received a MSc (Econs.), Accounting and Finance, from the London School of Economics.
Steven Bates was appointed to the board on 8 July 2015 and is Chairman of the Management Engagement Committee. He is the Chairman of Vietnam Opportunities Fund, of Baring Emerging Europe plc and of F&C Capital and Income Investment Trust. Other directorships held by him include British Empire Securities & General Investment Trust, and GuardCap Asset Management Ltd. He has a wealth of experience as an investment manager and sits on or is adviser to various committees in the wealth management and pension fund worlds. Previously he was head of global emerging markets at JP Morgan Asset Management.
Peter Keen has served on the Board as a Director since the launch of the Company in June 1997 and is Chairman of the Audit & Management Engagement Committee. A chartered accountant, he has over 30 years’ experience in the management and financing of life science businesses. He is Chief Executive of the technology investment firm Cambridge Innovation Capital plc and has served on the Board of many private and public companies. He is currently a Director of MRC Technology Limited. For nine years he was the Senior Independent Director of Abcam plc and was a co-founder of Chiroscience Group plc.
Professor Dame Kay Davies, CBE
Professor Dame Kay Davies CBE joined the Board in March 2012 and is Chairman of the Remuneration Committee. She is the Dr Lee’s Professor of Anatomy and Associate Head of the Medical Sciences Division at the University of Oxford and a fellow of Hertford College. She is also a director of the MRC Functional Genomics Unit at Oxford, Deputy Chairman of the Wellcome Trust and an Independent Director of UCB Pharma S. A. where she is also Chair of the Scientific Advisory Board. Professor Davies also acts as a consultant to drug discovery company Summit plc.
Lord Willetts joined the Board in November 2015. He is Executive Chairman of the Resolution Foundation and a Visiting Professor at King's College London. He is Governor of the Ditchley Foundation and a member of the Council of the Institute for Fiscal Studies. He was Minister for Universities and Science, attending Cabinet, from 2010-2014. He was the Member of Parliament for Havant from 1992-2015. Before that, Lord Willetts worked at HM Treasury and the Number 10 Policy Unit. He also served as Paymaster General in the last Conservative Government.
Julia Le Blan
Julia Le Blan joined the Board on 12 July 2016. A Chartered Accountant, she is a non-executive director of Investors Capital Trust plc, Impax Environmental Markets plc, JP Morgan US Smaller Companies Investment Trust plc and Aberforth Smaller Companies Trust plc.
All Directors, with the exception of Sven Borho, are members of the Audit, Management Engagement, Nominations and Remuneration Committees.
Read about the anti-bribery and corruption policies here.